Welcome to our dedicated page for 60 degrees pharmaceuticals news (Ticker: SXTP), a resource for investors and traders seeking the latest updates and insights on 60 degrees pharmaceuticals stock.
60 Degrees Pharmaceuticals develops and commercializes medicines for vector-borne disease, led by ARAKODA® (tafenoquine), an FDA-approved malaria prevention drug for adults. Company news commonly covers ARAKODA access and marketing channels for U.S. travelers, including telehealth and prescription-savings arrangements, as well as financial results and capital-market actions tied to its Nasdaq-listed common stock and warrants.
Updates also address tafenoquine development beyond malaria prophylaxis, including reports from studies in relapsing babesiosis, and work involving Australian Chestnut Extract, castanospermine and celgosivir-related research for non-prescription or infectious-disease applications. The company’s announcements frequently combine product availability, regulatory interactions, license arrangements, clinical data and corporate-structure matters such as reverse stock split actions.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported early enrollment of the first 2026 tick-season patient in its randomized, double-blind, placebo-controlled trial of tafenoquine for hospitalized babesiosis. Enrollment is about one month ahead of schedule, with at least 24 patients targeted before an interim analysis.
The study at five Northeastern U.S. sites has two main endpoints: clinical symptom resolution and parasite clearance, each with separate interim analyses. Minimum enrollment for interim review could be reached by early July 2026. Tafenoquine is FDA-approved for malaria prophylaxis but not for babesiosis.
60 Degrees Pharmaceuticals (NASDAQ:SXTP) reported first quarter 2026 results for the period ended March 31, 2026.
Net product revenues were approximately $162 thousand, down about 1% year over year. Gross profit was $76 thousand. Operating expenses rose to $2.17 million, and net loss attributable to common shareholders was $2.21 million, or $1.28 per share.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced on April 15, 2026 that ARAKODA (tafenoquine) for malaria prevention is now available to U.S. travelers through the Runway Health telehealth website. Patients can consult a licensed clinician on Runway Health, obtain a prescription if appropriate, and receive delivery prior to travel.
ARAKODA is an FDA-approved once-weekly, broad-spectrum malaria preventive for adults 18+, offered as an alternative to daily prophylaxis after an initial loading phase.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported FY2025 results on March 31, 2026, with net product revenues up 65% to $1.005 million and gross profit of ~$223.8k. Operating expenses fell to ~$8.4 million, and net loss improved to ~$7.37 million. The company raised ~$4.03 million via its ATM, exhausting current shelf capacity.
Clinical and commercial progress included expanded access cures for relapsing babesiosis, pharmacy partnerships with GoodRx and Runway Health, a Phase 2 site opening, and a Yale tafenoquine license.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) submitted a New Dietary Ingredient Notification (NDIN) to the FDA on March 11, 2026, for an Australian Chestnut Extract product; FDA review runs through May 25, 2026.
The company also signed an option to license Florida State University capsule formulation methods and previously exercised a January 2026 license option for large-scale purification rights for castanospermine.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) reported that all three patients in its expanded‑use trial of tafenoquine for relapsing babesiosis in immunosuppressed patients achieved cure after completing the regimen.
The open‑label study used weekly tafenoquine added to atovaquone‑containing combinations sustained until two consecutive negative PCRs; combined data with a 2024 Yale report suggest near 100% cure in seven patients. Tafenoquine is not FDA‑approved for babesiosis and is approved in the U.S. for malaria prophylaxis as ARAKODA.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) partnered with GoodRx (Nasdaq: GDRX) to offer eligible patients savings of up to 30% on ARAKODA® (tafenoquine), effective Feb 2, 2026. The program expands access at more than 70,000 pharmacies nationwide and may include home delivery where available.
This collaboration aims to lower out-of-pocket costs and broaden the company’s marketing reach for its FDA-approved, once-weekly malaria prevention therapy for travelers to endemic regions.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) exercised its option with Florida State University to negotiate an exclusive license for large-scale purification of castanospermine from Castanospermum australe seeds.
The company completed safety testing, developed prototype oral capsules, and is ready to commence a regulatory process to seek U.S. market access as a botanical non-prescription product. Prior clinical history tied to celgosivir involved more than 500 patients, which the company cites when noting human safety at achievable doses.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) announced a partnership with Runway Health to expand pre-departure access to ARAKODA® (tafenoquine) for malaria prevention among international travelers. ARAKODA is described as the only FDA-approved, broad-spectrum, once-weekly prescription malaria prevention on the U.S. market. Runway Health will offer physician-led online consultations and, if prescribed, seamless home delivery that arrives before departure. The partnership commences April 2, 2026 and lets eligible users match travel itineraries with personalized treatment plans designed by a U.S.-licensed healthcare provider.
60 Degrees Pharmaceuticals (NASDAQ: SXTP) will effect a one-for-four (1:4) reverse stock split of its common stock, effective January 20, 2026 at 12:01 AM ET, before market open. The company said the reverse split is intended to bring SXTP into compliance with Nasdaq's minimum bid price requirement. The reverse split will change the CUSIP to 83006G500, reduce outstanding shares from approximately 5,148,767 to approximately 1,287,192, and adjust all outstanding options, warrants, restricted stock awards and equity plan share counts. Par value and authorized share totals remain unchanged. Fractional shares will be rounded up to the next whole share.